This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Samyang Biopharmaceuticals Corporation
ClinicalTrials.gov Identifier:
NCT00882973
First received: April 16, 2009
Last updated: May 2, 2017
Last verified: May 2017
  Purpose
This is a phase I/II trial to determine the maximum tolerated dose and recommended phase II dose of the combination therapy with Genexol-PM and gemcitabine (hereafter Genexol-PM plus gemcitabine) and to evaluate the efficacy and safety of Genexol-PM regimens (monotherapy and combination with gemcitabine) and gemcitabine monotherapy in subjects with locally advanced or metastatic pancreatic cancer.

Condition Intervention Phase
Pancreatic Cancer Drug: Genexol-PM Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Samyang Biopharmaceuticals Corporation:

Primary Outcome Measures:
  • The maximum tolerated dose (MTD) of the combination therapy with Genexol-PM and gemcitabine [ Time Frame: 1 year ]
  • The recommended phase II dose of the combination therapy with Genexol-PM and gemcitabine [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Objective response rate (complete response (CR) + partial response (PR)) [ Time Frame: 1 year ]
  • Time to tumor progression [ Time Frame: 1 year ]
  • Progression free survival [ Time Frame: 1 year ]
  • Safety profiles [ Time Frame: 1 year ]

Enrollment: 18
Actual Study Start Date: September 2008
Study Completion Date: November 2010
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1
Genexol-PM 220 mg/m2 + Gemcitabine 1,250 mg/m2
Drug: Genexol-PM
Cremophor EL-free polymeric micelle of paclitaxel
Experimental: Cohort 2
Genexol-PM 260 mg/m2 + Gemcitabine 1,250 mg/m2
Drug: Genexol-PM
Cremophor EL-free polymeric micelle of paclitaxel
Experimental: Cohort 3
Genexol-PM 300 mg/m2 + Gemcitabine 1,250 mg/m2
Drug: Genexol-PM
Cremophor EL-free polymeric micelle of paclitaxel

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects who aged 18 years or older
  2. Subjects whose written informed consent was obtained complying with the local regulatory requirements prior to their participation in the trial
  3. Subjects who have histologically or cytologically confirmed unresectable or metastatic epithelial cancer of the exocrine pancreas. High-quality contrast-enhanced CT scanning is required to evaluate resectability. Measurable disease is not required.
  4. Subjects with no other malignancy diagnosed within past five years except for:

    • Cured non-melanoma skin cancer
    • Cured cervical intraepithelial neoplasia (CIN)
    • Cured In-situ cervical cancer (CIS)
  5. Subjects who are ECOG performance status of ≤ 1
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Samyang Biopharmaceuticals Corporation
ClinicalTrials.gov Identifier: NCT00882973     History of Changes
Other Study ID Numbers: GPMPC202
Study First Received: April 16, 2009
Last Updated: May 2, 2017

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Gemcitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 21, 2017